Scrip 100 Analysis: Sales Up, Profits Down – But Is It Real?
Bellwethers tell you something, but to gauge the health of the pharmaceutical industry, you really need the Scrip 100. For FY 2016, it looks like drug sales are up again and profits are down. But is this what's actually going on?
Infographic: Scrip 100 Numbers Crunched
This year's Scrip 100 collection is bigger than ever, encompassing 2016 full-year financial data from more than 650 biopharmaceutical companies.
The full Scrip 100 data set for 2018 is now available and includes data on R&D spending, total revenues, assets, operating profit and sales for 659 biopharmaceutical companies.
If you are a Scrip subscriber, click here to download the data in Excel format.
Chapter sponsored by:
 |
Download Scrip 100 league table PDF
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.